- Home
- PMTS vs ABOS Comparison
PMTS vs ABOS Comparison
Compare PMTS & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMTS | ABOS |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.4M | 148.4M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMTS | ABOS |
|---|---|---|
| Price | $11.61 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $30.75 | $7.50 |
| AVG Volume (30 Days) | 35.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $312,189,000.00 | N/A |
| Revenue This Year | $13.70 | N/A |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $18.05 | ★ N/A |
| Revenue Growth | ★ 12.27 | N/A |
| 52 Week Low | $10.81 | $0.86 |
| 52 Week High | $34.25 | $3.05 |
Technical Indicators
Market Signals| Indicator | PMTS | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 33.29 | 57.27 |
| Support Level | $11.00 | $2.37 |
| Resistance Level | $12.20 | $2.65 |
| Average True Range (ATR) | 0.72 | 0.23 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 25.97 | 58.62 |
Price Performance
Historical ComparisonAbout PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.